Use of Adderall and Risperidone in Pregnancy
Both Adderall (amphetamine mixed salts) and risperidone can be continued during pregnancy if they are required for the daily functioning of the pregnant person, as the documented risks are very low and discontinuation may lead to worse maternal mental health outcomes that could negatively impact both mother and fetus.
Adderall (Amphetamine Mixed Salts) in Pregnancy
Safety Profile
The 2024 American Journal of Obstetrics and Gynecology guidelines provide the most comprehensive and recent evidence on amphetamine use during pregnancy 1. Amphetamines do not appear to be associated with major congenital malformations, including cardiac malformations, or other significant adverse obstetrical or developmental outcomes 1.
Specific Risks (Small and Inconsistent)
The evidence shows some possible associations, but these are either very small in magnitude or not consistently replicated:
- Gastroschisis: Possible increased risk (aOR 3.0; 95% CI 1.2-7.4), but this comes from only one study with possible confounding, and the absolute risk remains extremely small given the rarity of gastroschisis (population prevalence 0.05%) 1
- Preeclampsia: Possible small increased risk (aRR 1.29; 95% CI 1.11-1.49), though other studies have not found this association 1
- Preterm birth: Possible small increased risk when stimulant use continues in the second half of pregnancy (aRR 1.30; 95% CI 1.10-1.55) 1
Neurodevelopmental Outcomes
Recent high-quality research provides reassuring evidence. A 2025 population-based cohort study and meta-analysis found that ADHD medication use during pregnancy does not increase the risk of neurodevelopmental disorders in offspring 2. A 2024 study examining prescription stimulant use found no meaningful increase in autism spectrum disorder, ADHD, or other neurodevelopmental disorders after adjustment for confounders 3.
Clinical Management Algorithm
Preconception:
- Attempt gradual discontinuation if it won't severely impact daily functioning
- If unable to discontinue: continue current medication, reduce to lowest effective dose, consider intermittent use, or switch to nonstimulant 1
- Engage in thorough risk-benefit discussion 1
During Pregnancy:
- Continue well-tolerated, effective dose if needed for functioning 1
- Consider intermittent (as-needed) use to maximize functioning while reducing fetal exposure 1
- Monitor carefully: fetal growth, blood pressure, maternal weight gain 1
Key Principle: The consensus is that treatment should not be stopped if medications are required for daily functioning 1. Untreated ADHD carries its own risks, including increased spontaneous abortion and preterm birth 1.
Risperidone in Pregnancy
FDA Classification and Safety Data
Risperidone is FDA Pregnancy Category C 4. The FDA label states that adequate and well-controlled studies have not been conducted in pregnant women, but animal studies at 0.4-6 times the maximum recommended human dose showed no teratogenic effects 4.
Human Evidence
A large 2016 study of 1.36 million pregnancies found that after confounding adjustment, atypical antipsychotics as a class showed no increased risk for malformations (RR 1.05; 95% CI 0.96-1.16) 5. However, risperidone specifically showed a small increased risk in overall malformations (RR 1.26; 95% CI 1.02-1.56) and cardiac malformations (RR 1.26; 95% CI 0.88-1.81) that was independent of measured confounders 5.
A 2007 postmarketing review of 713 pregnancies with risperidone exposure found that organ malformations occurred in 3.8% of prospectively reported pregnancies with known outcomes—consistent with background rates in the general population 6.
Neonatal Considerations
Critical warning: Neonates exposed to antipsychotics (including risperidone) during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms following delivery 4. These can include:
- Agitation, hypertonia, hypotonia, tremor
- Somnolence, respiratory distress
- Feeding disorders
Some neonates recover within hours to days; others may require prolonged hospitalization 4. Monitor neonates carefully for these symptoms 4.
Clinical Decision-Making
The FDA label states: "Risperidone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus" 4.
Given the small but present signal for increased malformations with risperidone specifically (unlike the class as a whole), consider:
- Whether the indication is severe enough to warrant continued use
- Alternative antipsychotics with more reassuring data if switching is feasible
- Close monitoring if continued, including fetal echocardiography
- Preparation for potential neonatal complications if used in third trimester
Combined Use Considerations
When both medications are needed:
- The risks do not appear to be additive based on available evidence
- Each medication should be evaluated on its own merit for necessity
- Untreated severe psychiatric illness carries substantial risks to both mother and fetus, including poor prenatal care, substance use, and adverse pregnancy outcomes 1
- Use the lowest effective doses of each medication
- Consider intermittent dosing strategies where clinically appropriate 1
Common Pitfalls to Avoid
- Automatic discontinuation: Don't reflexively stop medications without assessing functional impairment risk 1
- Ignoring maternal illness risk: Untreated ADHD and psychosis carry their own fetal risks 1
- Inadequate monitoring: Must monitor fetal growth, maternal blood pressure, and neonatal status closely 1
- Failing to plan for delivery: Prepare neonatal team for potential withdrawal/extrapyramidal symptoms with risperidone 4